Stoke Therapeutics, Inc.

Stoke Therapeutics is a biotechnology company focused on developing treatments for severe genetic diseases by upregulating protein expression. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach uses antisense oligonucleotides (ASOs) to selectively restore protein levels. The company's lead product candidates include Zorevunersen (STK-001), an investigational medicine for Dravet syndrome currently in Phase 3 clinical trials, and STK-002, which is in Phase 1 trials for autosomal dominant optic atrophy. Stoke also has preclinical programs targeting haploinsufficiency diseases of the central nervous system and the eye.

Stoke Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol STOK. The company trades in U.S. dollars (USD), as it is headquartered in the United States and its primary listing is on a U.S. exchange.

Stoke Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies for severe genetic diseases using advanced RNA-based technologies, such as antisense oligonucleotides.

Stoke Therapeutics is headquartered in Bedford, Massachusetts, United States. The company was incorporated in 2014 and was originally known as ASOthera Pharmaceuticals, Inc. before rebranding to Stoke Therapeutics in May 2016. Its operations are primarily based in the U.S., and it serves global markets through collaborations.

Stoke Therapeutics has established significant collaborations to advance its pipeline. It has a license and collaboration agreement with Biogen Inc. for the development and commercialization of zorevunersen (STK-001) for Dravet syndrome. Additionally, it partners with Acadia Pharmaceuticals Inc. to discover, develop, and commercialize novel RNA-based medicines for genetic neurodevelopmental diseases. The company's business model focuses on leveraging its proprietary TANGO platform to create therapies for haploinsufficiency disorders, with potential revenue from partnerships, milestone payments, and future product sales.